Consumer Reports Magazine Says: Skip Actos

As Actoslitigation continues to grow, more researchers are investigating the benefits and dangers associated with this diabetes medication.  Researchers across the globe have been busy publishing articles exposing the links to bladder cancer, heart attacks, and opinions regarding their effectiveness.

In August, 2012, the Consumer Reports Magazine boldly declared, “We say skip Actos as both a generic and brand- name medication, unless other options have failed.”  With a long history of exposing questionable products to the public, this Consumer Reports Magazine criticism carries the weight of a consumer first publication. 

Actos Bladder Cancer Claims

Actos (Piaglitazone) is a popular type 2 diabetes medication which came under fire from the U.S. Food and Drug Administration in June 2011.  Pioglitazone is sold in combination with metformin under the brand names:  Actoplus Met, Actoplus Met XR and Duetact (combining glimepiride in this formula.)

Many studies, including Kaiser Permanente’s 10 year study of thousands of patients, have linked Actos to bladder cancer.  In this study, Kaiser found that Actos patients had as much as a 40% increase in risk for bladder cancer.

In response to this FDA safety communication, injured Actos patients have filed suit across the country.  Patients allege their bladder cancer is the direct result of taking Actos for an extended period of time.  Further claims are also emerging that other kinds of cancer, including renal cancer and pancreatic cancer may also be linked to Actos.

What to Do if You Have Been Injured By Actos

If you have contracted bladder cancer as a result of taking Actos, you could be entitled to compensation for your injuries.  You should call an experienced attorney to fight for your rights today.  Don’t suffer the ill effects of bladder cancer and watch your finances and quality of life dwindle.  Take your life back and call experienced Actos injury attorneys today.